Français
DeutschMore on PC1 for HIV/AIDS
Introduction
The resonance treatment of epidemics is based on the genus epidemicus principle, which means that a remedy is chosen based on similarity to the totality of the symptoms of an infectious disease.
In 2001 the British homeopath Peter Chappell went to Ethiopia and took 70 cases of AIDS to determine the genus epidemicus of HIV/AIDS in Africa.
In short he found these primary characteristics (for a more extensive description see his book The Second Simillimum):
- Weakness, loss of strength, can't walk far, can't work much, can't look after themselves fully, and finally not at all.
- Later on a loss of appetite from a fungal infection in mouth and digestive tract.
- Loss of weight independent of appetite.
- Reduced recovery powers.
- Chronicity of every symptom; normal acutes like headaches and coryza become permanent.
- Dying is usually from starvation as they physically cannot eat.
Comparing the results of his analysis with the available homeopathic remedy pictures it appeared that there was no known homeopathic remedy that covered the totality of HIV/AIDS.
Designing a remedy for HIV/AIDS
Peter then decided to create a new technology to design a remedy. He figured out how to reverse engineer the totality and essence of the symptom picture information and the medical disease description into a remedy for HIV/AIDS he later called PC1. In this new technology the specification of the information concerning the disease carried within water that the patient receives is based upon the information needed to stimulate a healing response exactly appropriate to the disease, which is based on the principle of resonance, as is also in all homeopathic medicine.
Advantages
Resonance remedies have a very high safety protocol (Food and Drug Administration, United States of America) and have no side effects. The remedy can therefore be safely used by children, the elderly as well as pregnant women. Since PC1 is based on the principle of one remedy for a disease the skills that are needed to prescribe and follow up the case are minimal. Together with the very low costs of producing the remedy this makes PC1 an ideal alternative and complement for the treatment of HIV/AIDS in developing countries.
Not for profit
The intellectual property rights of the AIDS medicine (PC1) in particular are owned by the ARHF. PC1 is provided by the foundation for research and treatment at a not-for-profit basis. In practice this means that patients can be treated for 1-2 euros per month.
Results
The clinical results of this new AIDS treatment using PC1 have been observed in Africa since 2001 - Rwanda, The Congo, Cameroon, South Africa, Swaziland, Uganda, Malawi, Kenya, Central African Republic, Ethiopia etc. Also from India positive reports have been received.
A retrospective study by Corrie Hiwat and Harry van der Zee done in Malawi in 2004 was published in Homoeopathic Links (issue 4/2004). We are now in the process of building hard science based results to consolidate this new technology for the benefit of humanity. In cooperation with the government of the Central African Republic, the Global Fund and universities in Europe a study protocol was designed in 2006. In the summer of 2006 a first pilot was done in Bangui. Conduction the full study is aimed to take place in Africa as well as India.
General practical instructions
The remedy is available as globules, from which a dilution can be made, and as a ready-for-use dilution in a dropper bottle. Patients take 5 drops of the remedy daily after banging the bottle five times (normal procedure for homeopathic dilutions). Easy instructions for doctors and patients are provided.
Patients using PC1 besides anti-retro-viral drugs report less side-effects from the ARVs and do better or sometimes much better than on ARVs alone.
